{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:29Z","timestamp":1785466709118,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01442-w","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:44:10Z","timestamp":1782207850000},"page":"2643-2657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report"],"prefix":"10.1007","volume":"15","author":[{"given":"Katharina","family":"Heck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Magnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Stasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Shamshiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine A.","family":"Zweifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor M.","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-3003","authenticated-orcid":false,"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1442_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22608\/APO.2017442","volume":"7","author":"M Ip","year":"2018","unstructured":"Ip M, Hendrick A. Retinal vein occlusion review. Asia Pac J Ophthalmol (Phila). 2018;7:40\u20135. https:\/\/doi.org\/10.22608\/APO.2017442.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"1442_CR2","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","volume":"396","author":"IU Scott","year":"2020","unstructured":"Scott IU, Campochiaro PA, Newman NJ, Biousse V. Retinal vascular occlusions. Lancet. 2020;396:1927\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(20)31559-2.","journal-title":"Lancet"},{"key":"1442_CR3","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9:010427. https:\/\/doi.org\/10.7189\/jogh.09.010427.","journal-title":"J Glob Health"},{"key":"1442_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011;25:981\u20138. https:\/\/doi.org\/10.1038\/eye.2011.92.","journal-title":"Eye (Lond)"},{"key":"1442_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica. 2019;242:123\u201362. https:\/\/doi.org\/10.1159\/000502041.","journal-title":"Ophthalmologica"},{"key":"1442_CR6","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1172\/JCI66549","volume":"123","author":"T Ziegler","year":"2013","unstructured":"Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, Dietzel S, et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest. 2013;123:3436\u201345. https:\/\/doi.org\/10.1172\/JCI66549.","journal-title":"J Clin Invest"},{"key":"1442_CR7","doi-asserted-by":"publisher","first-page":"e10666","DOI":"10.15252\/emmm.201910666","volume":"11","author":"JT Regula","year":"2019","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2019;11:e10666. https:\/\/doi.org\/10.15252\/emmm.201910666.","journal-title":"EMBO Mol Med"},{"key":"1442_CR8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024;131:950\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029.","journal-title":"Ophthalmology"},{"key":"1442_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/OPTH.S163859","volume":"12","author":"JM Jumper","year":"2018","unstructured":"Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol. 2018;12:621\u20139. https:\/\/doi.org\/10.2147\/OPTH.S163859.","journal-title":"Clin Ophthalmol"},{"key":"1442_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s10384-025-01237-9","volume":"69","author":"T Hikichi","year":"2025","unstructured":"Hikichi T, Kurabe H, Notoya A, Oguro Y, Hirano M, Doi Y. Short-term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion. Jpn J Ophthalmol. 2025;69:918\u201325. https:\/\/doi.org\/10.1007\/s10384-025-01237-9.","journal-title":"Jpn J Ophthalmol"},{"key":"1442_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12886-026-04695-y","volume":"26","author":"A Kilani","year":"2026","unstructured":"Kilani A, Assaf A, Vogt D, Vounotrypidis E, Parlak M, Jochem C, et al. Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study. BMC Ophthalmol. 2026;26:114. https:\/\/doi.org\/10.1186\/s12886-026-04695-y.","journal-title":"BMC Ophthalmol"},{"key":"1442_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10792-025-03836-4","volume":"45","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhao M, Miao H, Qi H. Real-life short-term experience of switching from other anti-VEGF therapy to faricimab in patients with refractory macular edema secondary to retinal vein occlusion in China. Int Ophthalmol. 2025;45:463. https:\/\/doi.org\/10.1007\/s10792-025-03836-4.","journal-title":"Int Ophthalmol"},{"key":"1442_CR13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40123-026-01338-9","volume":"15","author":"A \u00c7ak\u0131r","year":"2026","unstructured":"\u00c7ak\u0131r A, Akkan F, Kapran Z, \u00dcnal M, \u015eerif N, Uzundede T, et al. Real-world 6-month treatment outcomes of faricimab in Turkey: the FARTURK study. Ophthalmol Ther. 2026;15:1165\u201377. https:\/\/doi.org\/10.1007\/s40123-026-01338-9.","journal-title":"Ophthalmol Ther"},{"key":"1442_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-026-00804-7","volume":"12","author":"L Wu","year":"2026","unstructured":"Wu L, Rojas S, Rao X, Politis M, Roca JA, Nehemy M, et al. Early latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group. Int J Retina Vitreous. 2026;12:48. https:\/\/doi.org\/10.1186\/s40942-026-00804-7.","journal-title":"Int J Retina Vitreous"},{"key":"1442_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/jcm14072454","volume":"14","author":"M Hafner","year":"2025","unstructured":"Hafner M, Herold TR, Kufner A, Asani B, Ansch\u00fctz A, Eckardt F, et al. Switching to faricimab in therapy-resistant macular edema due to retinal vein occlusion: initial real-world efficacy outcomes. J Clin Med. 2025;14:2454. https:\/\/doi.org\/10.3390\/jcm14072454.","journal-title":"J Clin Med"},{"key":"1442_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/11206721261444780","author":"P Wolfrum","year":"2026","unstructured":"Wolfrum P, B\u00f6hm EW, Welzel AM, K\u00f6nig S, Lorenz K, Stoffelns B, et al. Short-term clinical outcomes after switching to faricimab in patients affected by macular edema secondary to retinal vein occlusion: a real-world study. Eur J Ophthalmol. 2026. https:\/\/doi.org\/10.1177\/11206721261444780.","journal-title":"Eur J Ophthalmol"},{"key":"1442_CR17","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.2147\/OPTH.S549896","volume":"19","author":"S Inokuchi","year":"2025","unstructured":"Inokuchi S, Mizuki Y, Kamata A, Onishi J, Hayashi T, Mizuki N. Real-world efficacy of intravitreal faricimab for macular edema secondary to retinal vein occlusion: short-term outcomes and optical coherence tomography biomarker analysis. Clin Ophthalmol. 2025;19:3669\u201379. https:\/\/doi.org\/10.2147\/OPTH.S549896.","journal-title":"Clin Ophthalmol"},{"key":"1442_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","volume":"11","author":"T Hirakata","year":"2025","unstructured":"Hirakata T, Toride A, Ashikaga K, Nakagawa T, Hara F, Nochi Y, et al. Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion. Int J Retina Vitreous. 2025;11:79. https:\/\/doi.org\/10.1186\/s40942-025-00703-3.","journal-title":"Int J Retina Vitreous"},{"key":"1442_CR19","doi-asserted-by":"publisher","first-page":"e0335015","DOI":"10.1371\/journal.pone.0335015","volume":"20","author":"M Kondo","year":"2025","unstructured":"Kondo M, Shimura M, Tsujikawa A, Muraoka Y, Kogo T, Akiyama Y, et al. A multicenter, single-arm study using a modified faricimab treat-and-extend regimen in patients with macular edema due to central retinal vein occlusion: RVOSTAR study design protocol. PLoS ONE. 2025;20:e0335015. https:\/\/doi.org\/10.1371\/journal.pone.0335015.","journal-title":"PLoS ONE"},{"key":"1442_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.oret.2025.10.019","volume":"10","author":"M Lakhani","year":"2026","unstructured":"Lakhani M, Popovic MM, Al-Ani A, Kundapur D, Gholamian T, Chaudry E, et al. Comparative analysis of ocular adverse events between aflibercept 8 mg and faricimab: a global population-based study across 65 countries. Ophthalmol Retina. 2026;10:373\u201384. https:\/\/doi.org\/10.1016\/j.oret.2025.10.019.","journal-title":"Ophthalmol Retina"},{"key":"1442_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000487489","volume":"60","author":"M-M Guichard","year":"2018","unstructured":"Guichard M-M, Xavier AR, T\u00fcrksever C, Pruente C, Hatz K. Spectral-domain optical coherence tomography-driven treat-and-extend and pro re nata regimen in patients with macular oedema due to retinal vein occlusion: 24-month evaluation and outcome predictors. Ophthalmic Res. 2018;60:29\u201337. https:\/\/doi.org\/10.1159\/000487489.","journal-title":"Ophthalmic Res"},{"key":"1442_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30:1046\u201350. https:\/\/doi.org\/10.1097\/IAE.0b013e3181d87e04.","journal-title":"Retina"},{"key":"1442_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47:1236. https:\/\/doi.org\/10.1167\/iovs.05-0981.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1442_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","volume":"247","author":"C Lange","year":"2009","unstructured":"Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the freiburg visual acuity test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247:137\u201342. https:\/\/doi.org\/10.1007\/s00417-008-0926-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1442_CR25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology. 2015;122:1426\u201337. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.006.","journal-title":"Ophthalmology"},{"key":"1442_CR26","doi-asserted-by":"publisher","first-page":"176691","DOI":"10.1016\/j.ejphar.2024.176691","volume":"976","author":"A Kuriyama","year":"2024","unstructured":"Kuriyama A, Nakamura S, Inokuchi Y, Abe H, Yasuda H, Hidaka Y, et al. The protective effect of anti-VEGF-A\/Ang-2 bispecific antibody on retinal vein occlusion model mice. Eur J Pharmacol. 2024;976:176691. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176691.","journal-title":"Eur J Pharmacol"},{"key":"1442_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-026-04808-7","author":"S Fischer","year":"2026","unstructured":"Fischer S, Hoffmann L, Hatz K. Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion. BMC Ophthalmol. 2026. https:\/\/doi.org\/10.1186\/s12886-026-04808-7.","journal-title":"BMC Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01442-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01442-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01442-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:05:16Z","timestamp":1785463516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01442-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01442-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katja Hatz: Advisory board participant and lecturer for Apellis, Bayer, Roche, AbbVie\/Allergan, Astellas, Sandoz; contract research and\/or grant support for Bayer, Roche, AbbVie\/Allergan, ONL Therapeutics, Merck. Andreas Weinberger: Paid consultant and\/or lecturer for AbbVie, Appelis, Bayer, Roche, Sandoz. Sandrine A. Zweifel: Consultant and advisor for Alcon, Allergan, Apellis, Bayer, Endogena, Novartis, Roche, and Zeiss and grant support from Bayer, Novartis, and Roche outside the submitted work. Justus G. Garweg: Advisor and speaker for several pharmaceutical companies. Contributes to several international industry-sponsored clinical studies in the fields of retinal disease and uveitis (AbbVie, Bayer, EyeBio\/MSD, Roche). Grant support from Roche. Chiara M. Eandi: Advisory board participant and lecturer for AbbVie, Apellis, Astellas, Bayer, and Roche. Gabriela Grimaldi: Consultant for Apellis, Bayer, Roche. Lecturer for AbbVie, Apellis, Bayer, Roche. Grant support from Bayer and Roche. Marion R. Munk: Consultant for AbbVie, Allergan, 50 Acucela, Aviceda Therapeutics, Alimera, Bayer, Lumithera, OD-OS, Isarna Therapeutics, Roche, Novartis, Oculis, Ocuterra, genesight Therapeutics, Kubota, B\u00f6hringer-Ingelheim, Eyepoint, Ocular Therapeutix, Apellis, Astellas, Zeiss, RetinAI, Dandelion. Gabor M Somfai: Consultant for Apellis, Allergan, Bayer, Carl Zeiss, Roche. Aude Ambresin: Financial support: Roche, Bayer. Consultancy: Roche, Bayer, AbbVie, Ikerian, Appelis, Astellas. Nicolas Feltgen: Consultant for Apellis, Bayer, Roche, AbbVie. Katharina Heck, Marco Cattaneo, Isabel Pfister, Simon Magnin, Ludovico Ruscitti, Isabel Stasik, Anne Tillmann, Marat Shamshiev and Joseph Fang have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by all participating ethics committees, led by the Ethics Committee of the canton of Berne (registration no. 2024\u201301026). Coded patient data were included based on general or specific informed consent, in line with the International Council for Harmonisation Good Clinical Practice (ICH-GCP) E6 guidelines, the Declaration of Helsinki, and Swiss law.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}